시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 복잡성 요로감염증 치료 시장 보고서(2025년)
Complicated Urinary Tract Infection Treatment Global Market Report 2025
상품코드 : 1720766
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,344,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,170,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,996,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

복잡성 요로감염증 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 6.4%로 성장할 전망이며, 121억 3,000만 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 다제내성 병원체 만연, 정밀의료에 대한 관심 고조, 헬스케어 지출 증가, 신속진단 검사 이용 확대, 정부의 대처, 조사에 대한 자금 제공 등의 요인에 의한 것으로 생각됩니다. 이 시기의 주요 동향으로는 진단기술의 발전, 신흥국 시장에서 의료 접근성 확대, 신규 항생물질 개발, 진단도구 기술혁신, 병용요법의 채택 등을 들 수 있습니다.

만성 신장병(CKD)의 유병률 증가가 복잡성 요로감염증 치료 시장의 성장을 견인할 것으로 예측됩니다. CKD는 시간이 지남에 따라 신장 기능이 서서히 저하되는 장기적인 질환입니다. CKD 환자의 증가는 당뇨병, 고혈압, 고령화, 비만이나 흡연 등 라이프스타일 요인의 증가에 기인합니다. 복잡성 요로감염증 치료는 신장장애를 악화시키고, 신장기능을 저하시키며, CKD의 진행을 가속화시키는 신우신염 등 중증감염병을 예방하는데 도움이 되므로 CKD 환자에게 매우 중요합니다. 이 치료에 의해 추가적인 합병증이나 입원의 위험이 줄어듭니다. 예를 들어 2024년 12월 호주 보건복지연구소는 2022년 호주에서 약 2만 1800명이 CKD로 사망했다고 보고했습니다. 게다가 2024년 5월, Kidney Care UK는 영국에서는 만성 신장병이 매년 4만-4만 5,000명의 조기 사망 원인이 되고 있다고 말했습니다. 이처럼 CKD의 이환율 상승이 복잡성 요로감염증 치료 시장의 성장을 촉진하고 있습니다.

복잡성 요로감염증 치료 시장의 주요 기업은 치료 효과를 향상시키고 신흥 다제 내성 병원체에 대처하기 위한 새로운 항생제 개발을 통해 항생제 내성에 대처하는 데 주력하고 있습니다. 복잡성 요로감염증에 대한 항감염요법에서는 특히 신장이 침범된 중증 사례에서는 표적 항생제나 항균제를 사용하여 감염을 제어합니다. 예를 들면, 2024년 2월, 독일을 거점으로 하는 바이오 의약품 회사 Allecra Therapeutics사는, 미국 식품 의약국(FDA)이 성인의 복잡성 요로감염증 치료약으로서 EXBLIFEP(세페핌/엔메타조박탐)을 승인했다고 발표했습니다. 이 회사는 또, 신규 항감염증 치료제의 개발을 장려하는 GAIN법에 근거해, 5년간 독점 판매권의 연장도 획득했습니다. 임상시험에서는 세페핌 및 엔메타조박탐 투여군의 79.1%가 복합효과(임상적 치유 및 미생물학적 소실)를 달성한 반면, 피페라실린 및 타조박탐 투여군에서는 58.9%였습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Complicated urinary tract infection (UTI) treatment refers to the management of urinary tract infections in individuals with underlying conditions that increase the risk of treatment failure. This treatment involves using targeted antibiotics and supportive therapies to address infections caused by resistant pathogens or other complications. It is particularly used for severe UTIs in patients with structural abnormalities, immunocompromised conditions, or catheter use, ensuring effective infection control and preventing further complications.

The main drug types for complicated urinary tract infection treatment include penicillin and combinations, quinolones, cephalosporins, azoles and amphotericin B, and nitrofurans. Penicillin and combinations consist of antibiotics derived from penicillin, often combined with beta-lactamase inhibitors to enhance their effectiveness against resistant bacteria. These treatments are distributed through various channels, such as hospital pharmacies, gynecology and urology clinics, and drug stores. They are used for a range of conditions, including urethritis, cystitis, and pyelonephritis.

The complicated urinary tract infection treatment market research report is one of a series of new reports from The Business Research Company that provides complicated urinary tract infection treatment market statistics, including the complicated urinary tract infection treatment industry global market size, regional shares, competitors with the complicated urinary tract infection treatment market share, detailed complicated urinary tract infection treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the complicated urinary tract infection treatment industry. This complicated urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The complicated urinary tract infection treatment market size has grown strongly in recent years. It will grow from $8.87 billion in 2024 to $9.47 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historical period can be attributed to factors such as the increasing prevalence of urinary tract infections, a rise in cases of antibiotic resistance, a growing geriatric population, higher hospitalization rates, and greater awareness about UTIs.

The complicated urinary tract infection treatment market size is expected to see strong growth in the next few years. It will grow to $12.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be attributed to factors such as the growing prevalence of multidrug-resistant pathogens, an increasing focus on precision medicine, rising healthcare expenditure, greater use of rapid diagnostic testing, government initiatives, and funding for research. Key trends during this period include advancements in diagnostic techniques, expanding healthcare access in emerging markets, the development of novel antibiotics, technological innovations in diagnostic tools, and the adoption of combination therapies.

The increasing prevalence of chronic kidney disease (CKD) is expected to drive growth in the complicated urinary tract infection treatment market. CKD is a long-term condition marked by the gradual decline in kidney function over time. The rise in CKD cases is largely due to the growing rates of diabetes, hypertension, aging populations, and lifestyle factors such as obesity and smoking. Treatment for complicated urinary tract infections is crucial for CKD patients as it helps prevent severe infections such as pyelonephritis, which can worsen kidney damage, impair renal function, and accelerate the progression of CKD. This treatment reduces the risk of further complications and hospitalizations. For example, in December 2024, the Australian Institute of Health and Welfare reported that CKD was responsible for approximately 21,800 deaths in Australia in 2022. Moreover, in May 2024, Kidney Care UK stated that chronic kidney disease causes 40,000 to 45,000 premature deaths each year in the UK. Thus, the rising incidence of CKD is driving the growth of the complicated urinary tract infection treatment market.

Key companies in the complicated urinary tract infection treatment market are focusing on addressing antibiotic resistance through the development of novel antibiotics to improve treatment effectiveness and tackle emerging multidrug-resistant pathogens. Anti-infective therapies for complicated urinary tract infections involve using targeted antibiotics or antimicrobial agents to control infections, particularly in severe cases where the kidneys are affected. For instance, in February 2024, Allecra Therapeutics, a Germany-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved EXBLIFEP (cefepime/enmetazobactam) for treating complicated urinary tract infections in adults. The company also secured a five-year marketing exclusivity extension under the GAIN Act, which encourages the development of new anti-infective therapies. Clinical studies showed that 79.1% of patients treated with cefepime/enmetazobactam achieved a composite response (clinical cure and microbiological eradication), compared to 58.9% in those treated with piperacillin/tazobactam.

In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, partnered with Cipla Limited to launch cefepime/enmetazobactam in India. This collaboration aims to leverage Cipla's distribution network to enhance the availability of cefepime/enmetazobactam, an antibiotic used to treat complicated urinary tract infections, including pyelonephritis. Cipla, a prominent India-based pharmaceutical company, focuses on providing advanced antibiotics and innovative healthcare solutions for treating complicated urinary tract infections.

Major players in the complicated urinary tract infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline plc, bioMerieux SA, Shionogi & Co. Ltd., Cipla Limited, Santen Pharmaceutical Co. Ltd., Orchid Pharma Limited, Melinta Therapeutics Inc., Spero Therapeutics Inc., Nabriva Therapeutics AG, Venatorx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd, MerLion Pharmaceuticals Pte. Ltd., Entasis Therapeutics Holdings Inc., Allecra Therapeutics GmbH, Allergan Inc.

North America was the largest region in the complicated urinary tract infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in complicated urinary tract infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the complicated urinary tract infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The complicated urinary tract infection treatment market consists of sales of antibiotics, antifungals, and combination therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Complicated Urinary Tract Infection Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on complicated urinary tract infection treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for complicated urinary tract infection treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The complicated urinary tract infection treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Complicated Urinary Tract Infection Treatment Market Characteristics

3. Complicated Urinary Tract Infection Treatment Market Trends And Strategies

4. Complicated Urinary Tract Infection Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Complicated Urinary Tract Infection Treatment Growth Analysis And Strategic Analysis Framework

6. Complicated Urinary Tract Infection Treatment Market Segmentation

7. Complicated Urinary Tract Infection Treatment Market Regional And Country Analysis

8. Asia-Pacific Complicated Urinary Tract Infection Treatment Market

9. China Complicated Urinary Tract Infection Treatment Market

10. India Complicated Urinary Tract Infection Treatment Market

11. Japan Complicated Urinary Tract Infection Treatment Market

12. Australia Complicated Urinary Tract Infection Treatment Market

13. Indonesia Complicated Urinary Tract Infection Treatment Market

14. South Korea Complicated Urinary Tract Infection Treatment Market

15. Western Europe Complicated Urinary Tract Infection Treatment Market

16. UK Complicated Urinary Tract Infection Treatment Market

17. Germany Complicated Urinary Tract Infection Treatment Market

18. France Complicated Urinary Tract Infection Treatment Market

19. Italy Complicated Urinary Tract Infection Treatment Market

20. Spain Complicated Urinary Tract Infection Treatment Market

21. Eastern Europe Complicated Urinary Tract Infection Treatment Market

22. Russia Complicated Urinary Tract Infection Treatment Market

23. North America Complicated Urinary Tract Infection Treatment Market

24. USA Complicated Urinary Tract Infection Treatment Market

25. Canada Complicated Urinary Tract Infection Treatment Market

26. South America Complicated Urinary Tract Infection Treatment Market

27. Brazil Complicated Urinary Tract Infection Treatment Market

28. Middle East Complicated Urinary Tract Infection Treatment Market

29. Africa Complicated Urinary Tract Infection Treatment Market

30. Complicated Urinary Tract Infection Treatment Market Competitive Landscape And Company Profiles

31. Complicated Urinary Tract Infection Treatment Market Other Major And Innovative Companies

32. Global Complicated Urinary Tract Infection Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Complicated Urinary Tract Infection Treatment Market

34. Recent Developments In The Complicated Urinary Tract Infection Treatment Market

35. Complicated Urinary Tract Infection Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기